Research groups

GC08 Hormones and Cancer

The Hormones and Cancer research group is a consolidated group of the IMIBIC comprised by basic, translational, and clinical researchers. We investigate the cellular and molecular principles underlying the natural processes of neuroendocrine-metabolic regulation and their dysfunctions in tumors and cancer. The group pays special attention to the role played by certain neuropeptide/receptor systems and their regulation by distinct mechanisms, especially alternative splicing and its related RNA controlling processes and associated signalling pathways, at the onco-endocrine interface. The original focus of our group laid on the study of pituitary cell biology, particularly growth hormone (GH)-producing somatotropes and their regulatory signals (somatostatin, cortistatin, GHRH, ghrelin, Kisspeptins, etc.) and receptors (SST1-5, GHRHR, GHSR1, KISS1R), and signalling pathways. This line evolved to study pituitary neuroendocrine tumors (PitNETs) and expanded definitely with the discovery of novel, abnormal splicing variants (SST5TMD4, In1-ghrelin) and the study of their pathophysiological role in somatotropes and other endocrine cell types (eg. corticotropes, gonadotropes, pancreatic beta cells) and, broadly, in tumor development and metabolic dysfunction. Currently, our work is centred in the pathophysiology of neuroendocrine tumors (NETs) from pancreatic, gastrointestinal and lung origin, and of pancreatic ductal adenocarcinoma (PDAC), wherein we investigate the actions of diverse molecular regulatory systems (including somatostatin, ghrelin, etc.) and the specific role of alternative splicing and RNA biology.

To achieve our goals, we use a wide range of techniques, including primary cultures of normal and tumor cells, cell lines, genetically modified animals, measurements of peptides, hormones, second messengers and gene expression of diverse molecular components, particularly of the spliceosome machinery, as well as dynamic imaging of molecular trafficking, confocal microscopy in living cells, etc. We are developing and applying biocomputational approaches to explore the spliceosomic landscape in different experimental and clinical settings with the aim of further understanding the contribution of splicing and RNA metabolism to cancer and other diseases.

Our studies have led to the discovery and characterization of new receptors, splicing variants, functions and mechanisms of action for different neuroendocrine-metabolic signals and drugs controlling hormone secretion, tumorigenesis or cell death and survival in normal and pathological conditions, such as metabolic dysregulations (diabetes, obesity) and cancer (PitNETs, NETs, pancreatic cancer, and breast, prostate, and liver cancers, among others). Our ultimate aim is to contribute to the discovery of novel biomarkers for early detection, improved diagnosis and predictive prognosis of the tumors studied, as well as to identify actionable targets for the design of innovative personalized therapeutic strategies, which would jointly enable the advancement of precision medicine in NETs and pancreatic cancer.

Research Lines

Studies currently in progress in this field focus on the study of the dysregulation of the splicing machinery in neuroendocrine tumours from different locations, mainly pancreas, lung, gastrointestinal tract and hypophysis. In These tumour pathologies have shown the existence of characteristic splicing variants and preliminary studies indicate that there is a dysregulation in the machinery responsible for splicing, the spliceosome. The translational approach of these studies are also intended to assess the effect of current and new therapies for the treatment of neuroendocrine tumours on the genesis of new variants of alternative splicing, and the deregulation of alternative splicing variants, and the deregulation of the splicing machinery.

  • Identify the role of alternative splicing (components of the spliceosome, splicing factors and splicing variants) in the development and progression of neuroendocrine tumours and their response to treatment.
  • To explore the usefulness of its elements as potential new biomarkers for diagnosis, prognostic prediction, or targets for tumour treatment.
     

A second line of research focuses on the search for new diagnostic, prognostic and therapeutic biomarkers for pancreatic cancer. To achieve these objectives, we have worked on a multidisciplinary strategy that includes: clinical, histopathological and molecular characterisation ofclinical, histopathological and molecular characterisation of pancreatic ductal adenocarcinoma from both retrospective and prospective perspectives. 

The use of preclinical models of tumour development, and the use of primary crops and model cell lines, will help characterise the association and involvement of the alternative splicing system in this devastating pathology.

  • Characterisation of the involvement of the splicing-related molecular events and elements: alterations in spliceosome components, splicing factors and splicing variants, in the initiation, development and progression of pancreatic cancer.
  • To explore the possibility of using spliceosome components, splicing factors and/or splicing variants as molecular targets for the treatment of pancreatic cancer.
  • To identify biomarkers for the early diagnosis of pancreatic cancer using minimally invasive samples.

Networks

    CIBERobn - Physiopathology of Obesity and Nutrition

    GETNE - Spanish Group of Neuroendocrine Tumours – Spanish Society of Medical Oncology

    TransBioNet – Spanish Bioinformatics Network for Clinical Research

    SEEN - Area of Knowledge of Neuroendocrinology - Spanish Society of Endocrinology and Nutrition

    SAEDYN - Neuroendocrinology Work Group - Andalusian Society of Endocrinology, Diabetes and Nutrition

    ceiA3 - Agrifood Campus of International Excellence

    Rare Cancer Genomics

    ENETS - European Neuroendocrine Tumor Society - Advisory Board and Educational and Lung NET task forces 

    ESE - European Society of Endocrinology - Pituitary and Neuroendocrinology Focus Area. 

    REMAH - Spanish Molecular Registry of Hypophyseal Adenomas

    PAIDI BIO-139 Cellular and molecular endocrinology (Andalusian Plan for Research, Development and Innovation - PAIDI)

Keywords

  • cellular and molecular endocrine oncology
  • pancreatic cancer
  • neuroendocrine tumors
  • pituitary tumors
  • alternative splicing
  • splice-variants
  • spliceosome
  • somatostatin
  • somatostatin-receptors
  • cortistatin
  • ghrelin
  • signaling

Additional Information

Highlighted publications (2017-2019)

Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS.11.10.1439. DOI: 10.3390/cancers11101439. (Oncology) *Co-senior author
IF: 6,162    D2    Q1

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler MD, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018, 70(4):763-835.(Pharmacology & pharmacy)
IF: 18.886    D1

Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP*, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Mol Cancer 2017, 16(1):146. (Oncology) *Co-senior author
IF: 10.679    D1

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer 2017, 109:128-136. (Respiratory System)
IF: 4.599    Q1

Gahete MD, Del Rio-Moreno M, Camargo A, Alcalá-Diaz JF, Alors-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP*, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. EBioMedicine 2018, 3964(18)30479-1. (Medicine, Research & Experimental area) *Co-senior author
IF: 6.183    D1

Ongoing projects

Alterations in the alternative splicing machinery in pancreatic cancer: Identifications of novel diagnostic, prognostic and therapeutic biomarkers. BFU2016-80360-R.  PI: Justo P Castaño. Ministerio de Economía y Competitividad (MINECO). 2017-2019. 181.500€

Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. G1909. PI: Justo P Castaño. Beca GETNE 2019. 2020-2022. 60.000 €

IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño. (IMIBIC). 2019-2024. EC Funding: 662.040 €. (Total cost 1.183.680 €).

Promoting STEM vocations from Biomedicine. FCT-18-13958. PI: Justo P Castaño. FECYT. 2019-2020. 20.000€.

Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. FERP2019. PI: Justo P Castaño. Fundación Eugenio Rodríguez Pascual 2019. 2019-2020. 7.000 €

Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. PI: Cristina Morales Estévez. Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Proyectos de investigación traslacional en Inmuno-Oncología 2018). 2019-2020. 40.000€.

Diagnosis and personalized postoperative prognosis of human gliomas using a new interactive approach. PI-0143-2016. PI: Juan Solivera Vela. Consejería de Salud (Junta de Andalucía). 2017-2019. 46.970,42 €

Molecular and functional characterization of bladder cancer: search of novel therapies. PI: Raúl M Luque. Eli Lilly & Company. 46.200 €. 2019-20.

Ghrelin-O-acyl-Transferase (GOAT): New Biomarker for the screening of prostate cancer. DTS18/00131. PI: Raúl M Luque. Instituto de Salud Carlos III. Proyectos de Desarrollo Tecnológico en Salud. 2018-2020. 88.550€.

Ghrelin-O-aciltransferase (GOAT):  new biomarker for prostate cancer. (FIPSE Project 3188-17). PI: Raúl M Luque. 2018-2019. 30.000€.

Patents

Isoforms of the human somatostatin receptor type 5 produced by alternative processing and pairs of oligonucleotides for detection by PCR. Castaño JP, Durán Prado M, Martínez Fuentes AJ, Vázquez-Martínez R, García Navarro S, Gracia-Navarro F, Malagón MM. P200502701.

Ghrelin variant and its use. Luque RM, Castaño JP, Gahete MD, Gracia-Navarro F, Martínez-Fuentes AJ, Córdoba-Chacón J, Benito P, Kineman RD. P201030905.

Ghrelin-O-acyltransferase (GOAT) and its use. Castaño JP, Luque RM, Gahete MD, Hormaechea-Agulla D, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J, Ibáñez-Costa A, Moreno MM, Valero-Rosa J. P201531731 - PCT/ES2016/070844

Non-invasive diagnostic method for cancer. Castaño JP, Luque RM, Gahete MD, Ibáñez-Costa A, Hormaechea-Agulla D, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J.P201631606 - PCT/ES2017/070797

Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies. Luque RM, Castaño JP, Gahete MD, del Río-Moreno M, Alors-Pérez E. P201730702 - PCT/ES2018/070361

Method for the prediction and prognostic of the development of type 2 diabetes mellitus. Castaño JP, Luque RM, Gahete MD, López-Miranda J, Pérez-Martínez P, Delgado-Lista J, García-Ríos A, Alcalá-Díaz JF, Yubero-Serrano E, Camargo-García A, del Río-Moreno M, Alors-Pérez E, Ventura-Soto S, Reyes-Pupo O. P201831095

Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. Castaño JP, Luque RM, Gahete MD, Pedraza-Arévalo S, del Río-Moreno M, Alors-Pérez E, Gálvez-Moreno MA, Herrera-Martínez A, Serrano-Blanch R. P201831039

Method for the diagnosis and prognosis of the development of prostate cancer. Castaño JP, Luque RM, Gahete MD, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201930104

Method of obtaining useful data for the diagnosis, stratification and / or follow-up of patients with rheumatoid arthritis. Castaño JP, Luque RM, López-Pedrera R, Pérez-Sánchez C, Collantes-Estévez E, Ortega-Castro R, Ibáñez-Costa A, Pedraza-Arévalo S, del Río-Moreno M, Barbarroja-Puerto N, Jimenez-Gomez Y. P201930123

Method for the diagnosis and prognosis of the development of brain tumors. Luque RM, Gahete MD, Fuentes-Fayos AC, Castaño JP, Ibáñez-Costa A, Vázquez-Borrego MC, López-López F, Blanco-Acebedo C, Solivera-Vela J, Toledano-Delgado A, Gálvez-Moreno MA. P201931147.

Projects

PROJECTS IN 2020

Ongoing projects

National

Justo Pastor Castaño Fuentes; Alteraciones de la maquinaria de splicing alternativo en cáncer de páncreas: Identificación de nuevos biomarcadores diagnósticos, pronósticos y terapeúticos.; Funding Agency: MINISTERIO DE ASUNTOS ECONÓMICOS Y TRANSFORMACIÓN DIGITAL; Reference: BFU2016-80360-R

Justo Pastor Castaño Fuentes; Estrategia spliceosómica para mejorar el diagnóstico, la clasificación y el tratamiento de los tumores neuroendocrinos pancreáticos; Funding Agency: GRUPO ESPAÑOL DE TUMORES NEUROENDOCRINO (GETNE); Reference: GETNE 2019 G1909

Justo Pastor Castaño Fuentes; Descifrando la heterogeneidad de los tumores neuroendocrinos mediante una aproximación spliceosómica y de biología del ARN:potencial valor diagnóstico y terapéutico; Funding Agency: AGENCIA ESTATAL DE INVESTIGACIÓN; Reference: PID2019-105201RB-I00

Justo Pastor Castaño Fuentes; Estrategia Spliceosómica para mejorar el diagnóstico, la clasificación y el tratamiento de los tumores neuroendocrinos pancreáticos; Funding Agency: FUNDACIÓN EUGENIO RODRIGUEZ PASCUAL; Reference: FERP_2019_001

Justo Pastor Castaño Fuentes; Beca Senior FSEEN para desarrollo de proyecto de investigación 2020 Justor Pastor Castaño; Funding Agency: FUNDACIÓN DE LA SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN; Reference: FSEEN-2020-002

PROJECTS IN 2019

Ongoing projects

National

Castaño JP. Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. Funding agency: Spanish Group for the Study of Neuroendocrine Tumors - GETNE 2019. Reference: G1909.

Castaño JP. Promoting STEM vocations from Biomedicine. Funding agency: Spanish Foundatiotion for Science and Technology-FECYT. Reference: FCT-18-13958.

Castaño JP. Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. Funding agency: Fundación Eugenio Rodríguez Pascual. Reference: G1909.

Morales-Estévez C (IP). Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. Funding agency: Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Reference: Proyectos de investigación traslacional en Inmuno-Oncología 2018

Valencia A (IP); Córdoba Node: Castaño JP. Consolidating the traslational bioinformatic Network TransBioNet (Research Networks). Spanish Ministry for Science, Innovation and Universities. RED2018-102404-T.

Gahete MD (IP). Identification of new diagnostic, prognostic and/or therapeutic targets associated with the dysregulation of splicing mechanisms in neuroendocrine pituitary tumors. Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN).

International

IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño. 2019-2024. EC Funding: 662.040 €. (Total cost 1.183.680 €) (IMIBIC). 2019-2024.

Publications

Publications in 2020

Vazquez-Borrego MC, L-Lopez F, Galvez-Moreno MA, Fuentes-Fayos AC, Venegas-Moreno E, Herrera-Martinez AD, Blanco-Acevedo C, Solivera J, Landsman T, Gahete MD, Soto-Moreno A, Culler MD, Castano JP, Luque RM. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells. NEUROENDOCRINOLOGY. 2020. 110 (1-2):70-82 DOI: 10.1159/000500812 
IF: 4,271 Q: 1

Vazquez-Borrego MC, Gupta V, Ibanez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado A, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japon MA, Barrera-Martin A, Vasiljevic A, Hill J, Zhang SW, Halem H, Solivera J, Raverot G, Galvez MA, Soto-Moreno A, . A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors. CLINICAL CANCER RESEARCH. 2020. 26 (4):957-969 DOI: 10.1158/1078-0432.CCR-19-2154 
IF: 10,107 Q: 1

Reyes O, Perez E, Luque RM, Castano J, Ventura S. A supervised machine learning-based methodology for analyzing dysregulation in splicing machinery: An application in cancer diagnosis. ARTIFICIAL INTELLIGENCE IN MEDICINE. 2020. 108 ():- DOI: 10.1016/j.artmed.2020.101950 
IF: 4,383 Q: 1

del Rio-Moreno M, Luque RM, Rangel-Zuniga OA, Alors-Perez E, Alcala-Diaz JF, Roncero-Ramos I, Camargo A, Gahete MD, Lopez-Miranda J, Castano JP. Dietary Intervention Modulates the Expression of Splicing Machinery in Cardiovascular Patients at High Risk of Type 2 Diabetes Development: From the CORDIOPREV Study. NUTRIENTS. 2020. 12 (11):- DOI: 10.3390/nu12113528 
IF: 4,546 Q: 1

Garcia-Martinez A, Fuentes-Fayos AC, Fajardo C, Lamas C, Camara R, Lopez-Munoz B, Aranda I, Luque RM, Pico A. Differential Expression of MicroRNAs in Silent and Functioning Corticotroph Tumors. JOURNAL OF CLINICAL MEDICINE. 2020. 9 (6):- DOI: 10.3390/jcm9061838 
IF: 3,303 Q: 1

Jimenez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gomez-Gomez E, Fuentes-Fayos AC, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Pedraza-Arevalo S, Gonzalez-Serrano T, Reyes O, Martinez-Lopez A, Sanchez-Sanchez R, Ventura S, Yubero-Serrano EM, R. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBIOMEDICINE. 2020. 51 ():- DOI: 10.1016/j.ebiom.2019.11.008 
IF: 5,736 Q: 1

Herrera-Martinez AD, Feelders RA, Van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Castano JP, de Herder WW, Hofland LJ. Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. NEUROENDOCRINOLOGY. 2020. 110 (5):351-363 DOI: 10.1159/000502200 
IF: 4,271 Q: 1

Yubero-Serrano EM, Fernandez-Gandara C, Garcia-Rios A, Rangel-Zuniga OA, Gutierrez-Mariscal FM, Torres-Pena JD, Marin C, Lopez-Moreno J, Castano JP, Delgado-Lista J, Ordovas JM, Perez-Martinez P, Lopez-Miranda J. Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial. PLOS MEDICINE. 2020. 17 (9):- DOI: 10.1371/journal.pmed.1003282 
IF: 10,1 Q: 1 D: 1

Flores-Martinez A, Venegas-Moreno E, Dios E, Remon-Ruiz P, Gros-Herguido N, Vazquez-Borrego MC, Madrazo-Atutxa A, Japon MA, Kaen A, Cardenas-Valdepenas E, Roldan F, Castano JP, Luque RM, Cano DA, Soto-Moreno A. Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features. JOURNAL OF CLINICAL MEDICINE. 2020. 9 (9):- DOI: 10.3390/jcm9093052 
IF: 3,303 Q: 1

Fuentes-Fayos AC, Vazquez-Borrego MC, Jimenez-Vacas JM, Bejarano L, Pedraza-Arevalo S, L-Lopez F, Blanco-Acevedo C, Sanchez-Sanchez R, Reyes O, Ventura S, Solivera J, Breunig JJ, Blasco MA, Gahete MD, Castano JP, Luque RM. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. BRAIN. 2020. 143 ():3273-3293 DOI: 10.1093/brain/awaa273 
IF: 11,337 Q: 1 D: 1

Vazquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martinez AD, Venegas-Moreno E, L-Lopez F, Fanciulli A, Moreno-Moreno P, Alhambra-Exposito MR, Barrera-Martin A, Dios E, Blanco-Acevedo C, Solivera J, Granata R, Kineman RD, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castano JP, Luque RM. Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors. NEUROENDOCRINOLOGY. 2020. 110 (44176):1028-1041 DOI: 10.1159/000505923 
IF: 4,271 Q: 1

Saez-Martinez P, Jimenez-Vacas JM, Leon-Gonzalez AJ, Herrero-Aguayo V, Hidalgo AJM, Gomez-Gomez E, Sanchez-Sanchez R, Requena-Tapia MJ, Castano JP, Gahete MD, Luque RM. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 2020. 9 (6):- DOI: 10.3390/jcm9061703 
IF: 3,303 Q: 1

Garces, MF; Buell-Acosta, JD; Rodriguez-Navarro, HA; Pulido-Sanchez, E; Rincon-Ramirez, JJ; Moreno-Ordonez, DC; Franco-Vega, R; Roncancio-Munoz, JS; Burgos-Cardenas, AJ; Lacunza, E; Castano, JP; Dieguez, C; Nogueiras, R; Sanchez, E; Caminos, JE. Serum angiopoietin-like 3 levels are elevated in obese non diabetic men but are unaffected during an oral glucose tolerance test. SCIENTIFIC REPORTS. 2020. 10 (1):- DOI: 10.1038/s41598-020-77961-8 
IF: 3,998 Q: 1

Publications in 2019

Herrera-Martínez AD, Pedraza-Arévalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP*, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019. 104. 1. 57-73. DOI:10.1210/jc.2018-01455.
IF: 5,605 Q:1

Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R. Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features. CANCERS. 2019. 11.10.1439. DOI: 10.3390/cancers11101439.  *Co-senior author
IF: 6,162 Q:1 D: 2

Del Río-Moreno M, Alors-Pérez E, De Souza PB, Prados-González ME, Castaño JP*, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. 2019. TRANSLATIONAL RESEARCH. 211. (147-160). DOI: 10.1016/j.trsl.2019.02.013. *Co-senior author
IF: 4,915 D: 1

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted systemic treatment of neuroendocrine tumors: Current options and future perspectives. 2019. DRUGS. 79. 1. 21-42. DOI: 10.1007/s40265-018-1033-0.
IF: 4,993 Q: 1

Herrera-Martínez AD, Hofland LJ, Moreno MAG, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. 2019. ENDOCRINE-RELATED CANCER. 26. 3. R157-R179. DOI:10.1530/ERC-18-0354.
IF: 4,774 Q: 1

Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-Gonzalez AJ, Saez-Martínez P, Alors-Pérez E, Fuentes-Fayos AC, Martínez-López A, Sánchez-Sánchez R, González-Serrano T, López-Ruiz DJ, Requena-Tapia MJ, Castaño JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. 2019. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001.
IF: 4,915 D1

Gómez-Gómez, E; Jiménez-Vacas, JM; Pedraza-Arévalo, S; López-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibáñez-Costa, A; León-González, AJ; Sánchez-Sánchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castaño, JP, Carrasco-Valiente, Luque RM. Oncogenic role of secreted engrailed homeobox 2 (EN2) in prostate cancer. 2019. JOURNAL OF CLINICAL MEDICINE.8.9.1400. DOI: 10.3390/jcm8091400.
IF: 5,688 D1

Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein M, Mesa J, Castaño JP, Luque RM, Simó R; Metabolic fingerprint of acromegaly and its potential usefulness in clinical practice. 2019. JOURNAL OF CLINICAL MEDICINE. 8.10.1549. DOI: 10.3390/jcm8101549.
IF: 5,688 D1

Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. 2019. BRITISH JOURNAL OF PHARMACOLOGY. 176 Suppl 1:S21-S141. doi: 10.1111/bph.14748.
IF: 6.583 D1

Fernández-Bedmar Z, Anter J, Alonso-Moraga A, Delgado de la Torre P, Luque de Castro MD, Millán-Ruiz Y, Sánchez-Frías M, Guil-Luna S. Red and white wine lees show inhibitory effects on liver carcinogenesis. 2019. MOLECULAR NUTRITION FOOD RESEARCH. 2019 63(9):e1800864
IF: 4.653 D1

Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical utility of ghrelin-o-acyltransferase (GOAT) enzyme as a diagnostic tool and potential therapeutic target in prostate cancer. 2019. JOURNAL OF CLINICAL MEDICINE.  22. 8. (12). DOI: 10.3390/jcm8122056.
IF: 5,583 D1

Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, L-López F, Ibáñez-Costa A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castaño JP, Luque RM; Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms. 2019. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056.
IF: 5,605 Q1

del Río-Moreno M, Alors-Pérez E, González-Rubio S, Ferrín G, Reyes O, Rodríguez-Peralvarez M, Saáchez-Frías ME, Sánchez-Sánchez R, Ventura S, López-Miranda J, Kineman RD, de la Mata M, Castaño JP, Gahete MD, Luque RM; Dysregulation of the splicing machinery is associated to the development of nonalcoholic fatty liver disease.2019.  JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021.
IF: 5,605 Q1

Venegas-Moreno E, Flores-Martínez A, Dios E, Vázquez-Borrego MC, Ibáñez-Costa A, Madrazo-Atutxa A, Japón MA, Castaño JP, Luque RM, Cano DA, Soto-Moreno A. E-cadherin expression is associated with somatostatin analogue response in acromegaly. 2019. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 5. (3088-3096). DOI: 10.1111/jcmm.13851.
IF: 4,658 Q1

Gahete MD, Jiménez-Vacas JM, Alors-P´rrez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arévalo S, Castaño JP, Luque RM. Mouse models of endocrine tumors. 2019. JOURNAL OF ENDOCRINOLOGY. 240. 3. (R73-R96). DOI: 10.1530/JOE-18-0571.
IF: 4,381 Q1

Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M. mTOR expression in liver transplant candidates with hepatocellular carcinoma: impact on histological features and tumour recurrence. 2019. Int J Mol Sci. 20(2). pii: E336
IF: 4.172 Q2

Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Moreno MAG, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ. Effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor cells. 2019. HORMONES & CANCER. 10. 43526. 107-119. DOI:10.1007/s12672-019-00361-6.
IF: 2,581 Q3

Fuentes-Fayos AC, García-Martínez A, Herrera-Martínez AD, Jiménez-Vacas JM, Vázquez-Borrego MC, Castaño JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. 2019. MINERVA ENDOCRINOLOGICA. 44. 2. (109-128). DOI: 10.23736/S0391-1977.19.02970-5.
IF: 1,817 Q4

Publications in 2018

Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Rev 2018, 70(4):763-835. IF: 18.886 (Decil 1; Pharmacology & pharmacy area)

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Pérez E, Pedraza-Arévalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) enzyme as a novel potential biomarker in gastroenteropancreatic neuroendocrine tumors. Clin Transl Gastroenterol 2018, 9(10):196. FI: 4.803. (Quartile 1; Medicine, Research& Experimental area)

Pedraza-Arévalo S, Gahete MD, Alors-Perez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018, 19(2)179-192. IF: 5. 516. (Quartile 1; Endocrinology and Metabolism area)

Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep 2018, 8(1):6173. FI: 4.011. (Quartile 1; Multidisciplinary Sciences area)

Gahete MD, Del Rio-Moreno M, Camargo A, Alcala-Diaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. EBioMedicine 2018, 3964(18)30479-1. IF: 6.680. (Decil 1; Medicine, Research & Experimental area)

Herrera-Martínez AD, Gahete MD, Pedraza-Arévalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018, 59(2):426-437. IF: 3.296. (Quartile 2; Endocrinology & Metabolism area)

Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM. The pituitary gland is a novel major site of action of metformin in non-human primates: A potential path to expand and integrate its metabolic actions. Cell Physiol Biochem 2018, 49(4):1444-1459. IF: 5.500. (Decil 1; Physiology area)

Vázquez-Borrego MC, Gahete MD, Martínez-Fuentes AJ, Fuentes-Fayos AC, Castaño JP, Kineman RD, Luque RM. Review. Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: lessons from human and non-human primate models. Mol Cell Endocrinol 2018, 463:4-22. IF: 3.693 (Quartile 2; Endocrinology & Metabolism area)     

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis 2018, 39(3):447-457. IF: 4.004. (Quartile 2; Oncology area)     

Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. J Cell Mol Med 2018, 22(11):5688-5697. FI: 4.658. (Quartile 1; Medicine, Research & Experimental area)

Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortes E, Madrazo-Atutxa A, Japon MA, Luque RM, Castaño JP, Cano DA, Soto-Moreno A. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 2018, 22(3)1640-1649. IF: 4.658. (Quartile 1; Medicine, Research & Experimental area)    

Jimenez-Lucena R, Rangel-Zuniga OA, Alcala-Diaz JF, Lopez-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castaño JP, Ordovas JM, Perez-Martinez P, Camargo A, Lopez-Miranda J. Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary HeartDisease Patients from the CORDIOPREV Study. Mol Ther nucleid acids 2018, 12:146-157. IF: 5.919. (Decil 1;   Medicine, research & experimental area)

Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, Alcala-Diaz JF, Perez-Martinez P, Jimenez-Lucena R, Castaño JP, Roche HM, Delgado-Lista J, Ordovas JM, Camargo A, Lopez-Miranda J. Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study. Mol Nutr Food Res 2018, 62(9):e1700960. IF: 4.653.  (Decil 1; Food Science and Technology area)

Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcala-Diaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castaño JP, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. J Gerontol A Biol Sci Med  2018, 73(3):327-332. IF: 4.711. (Quartile 1; Geriatrics & Gerontology area)

Publications in 2017

Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, Garcia-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. ONCOGENE. 2017. 36(14):1899-1907.
IF: 7,519 Q: 1 D: 1

Hormaechea-Agulla D, Gahete MD, Jimenez-Vacas JM, Gomez-Gomez E, Ibanez-Costa A, L-Lopez F, Rivero-Cortes E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sanchez-Sanchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. MOLECULAR CANCER. 2017. 16(1):146.
IF: 6,204 Q: 1 

Hormaechea-Agulla D, Jimenez-Vacas JM, Gomez-Gomez E, Lopez FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sanchez-Sanchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibanez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB JOURNAL. 2017. 31(11): 4682-4696.
IF: 5,498 Q: 1  D: 1

Luque RM, Lopez-Sanchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-Garcia M, Alvarez-Benito M, Lopez-Miranda J, Gahete MD, Castaño JP. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. ONCOTARGET. 2017. 8(46):81462-81474.
IF: 5,168 Q: 1 

Sarmento-Cabral A, L-Lopez F, Gahete MD, Castaño JP, Luque RM. Metformin reduces prostate tumor growth, in a diet-dependent manner, by modulating multiple signaling Pathways. MOLECULAR CANCER RESEARCH. 2017. 15(7):862-874.
IF: 4,974 Q: 1 

L-Lopez F, Sarmento-Cabral A, Herrero-Aguayo V, Gahete MD, Castaño JP, Luque RM. Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2017. 21(9):1893-1904.
IF: 4,499 Q: 1 

Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Salas RO, Serrano-Blanch R, Salvatierra A, Hofland LJ, Luque RM, Galvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. LUNG CANCER. 2017. 109:128-136.
IF: 4,294 Q: 1 

Sarmento-Cabral A, L-Lopez F, Luque RM. Adipokines and their receptors are widely expressed and distinctly regulated by the metabolic environment in the prostate of male mice: Direct role under normal and tumoral conditions. ENDOCRINOLOGY. 2017. 158(10):3540-3552.
IF: 4,283 Q: 1 

Ibanez-Costa A, Lopez-Sanchez LM, Gahete MD, Rivero-Cortes E, Vazquez-Borrego MC, Galvez MA, de la Riva A, Venegas-Moreno E, Jimenez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japon MA, Garcia-Arnes JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. SCIENTIFIC REPORTS. 2017. 7():42002.
IF: 4,259 Q: 1 

Sarmento-Cabral A, Peinado JR, Halliday LC, Malagón MM, Castaño JP, Kineman RD, Luque RM. Adipokines (Leptin, Adiponectin, Resistin) differentially regulate all hormonal cell types in primary anterior pituitary cell cultures from two primate species. SCIENTIFIC REPORTS. 2017. 7:43537.
IF: 4,259 Q: 1 

Pedraza-Arévalo S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. PROSTATE. 2017. 77(15):1499-1511.
IF: 3,82 Q: 1 

Ibanez-Costa A, Luque RM, Castaño JP. Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. GROWTH HORMONE & IGF RESEARCH. 2017. 33:23-27.
IF: 1,828 Q: 4 

Clinical Research

Active in 2019

Ensayo clínico multicéntrico, aleatorizado, controlado, con evaluador ciego, para evaluar la eficacia y la seguridad de un hidrogel que contiene extracto de hoja de olivo como tratamiento de úlceras cutáneas.
PI: Dr. Paloma Moreno Moreno

Members

Principal Investigator
Justo Pastor Castaño Fuentes

Researcher
Francisco García Navarro

Post-Doctoral Researchers
Alejandro Ibáñez Costa
Antonio Manuel Agraz Doblas
Sergio Pedraza Arévalo

Pre-Doctoral Researchers
María Inmaculada Berbel Díaz
Cristóbal José Blanco Acevedo
María Teresa Caro Cuenca
Ricardo Blázquez Encinas-Rey
Antonio Carlos Fuentes Fayos
Miriam García Díaz
Víctor García Vioque
Paloma Moreno Moreno
María Trinidad Moreno Montilla
José Carlos Padillo Cuenca
María Esther Sánchez Frías